Tamary Hannah, Dgany Orly
Professor of Pediatrics Director, Hematology Diagnostic and Research Laboratory Schneider Children's Medical Center of Israel Petah Tiqva, Israel
Director, Pediatric Hematology Diagnostic Laboratory Felsenstein Medical Research Center Beilinson Campus Petah Tiqva, Israel
Congenital dyserythropoietic anemia type I (CDA I) is characterized by moderate-to-severe macrocytic anemia presenting occasionally in utero as severe anemia associated with hydrops fetalis but more commonly in neonates as hepatomegaly, early jaundice, and intrauterine growth restriction. Some individuals present in childhood or adulthood. After the neonatal period, most affected individuals have lifelong moderate anemia, usually accompanied by jaundice and splenomegaly. Secondary hemochromatosis develops with age as a result of increased iron absorption even in those who are not transfused. Distal limb anomalies occur in 4%-14% of affected individuals.
DIAGNOSIS/TESTING: The diagnosis of CDA I is suspected based on hematologic findings and established with identification of biallelic pathogenic variants in or .
Intramuscular or subcutaneous injections of interferon IFN-α2a or IFN-α2b are given two or three times a week or peginterferon-α2b once a week to increase hemoglobin and decrease iron overload. Allogeneic bone marrow transplantation should be considered only in transfusion-dependent persons who are resistant to IFN therapy. Treatment of iron overload using iron chelation as necessary; laparoscopic cholecystectomy for biliary stones; treatment of scoliosis per orthopedist; calcium and vitamin D supplementation for osteoporosis; treatment of extramedullary hematopoiesis including regular blood transfusions, surgical debulking, or low-dose radiation; treatment of vision issues per ophthalmologist. Measurement of hemoglobin every three to six months and more frequently at the time of infections, measurement of bilirubin, iron, transferrin, and serum ferritin concentration every six to 12 months starting at age ten years to monitor anemia and iron overload; annual myocardial and liver T-weighted MRI starting at age ten years (if available). Annual abdominal ultrasound beginning at age five years; examination for scoliosis with orthopedist as needed; bone densitometry for osteoporosis as recommended by bone specialist; annual assessment of visual acuity and fundoscopic examination by ophthalmologist beginning at age 40 years or earlier if symptomatic. Any preparation containing iron.
CDA I is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a CDA I-causing pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal and preimplantation genetic testing are possible.
I型先天性红细胞生成异常性贫血(CDA I)的特征为中度至重度大细胞性贫血,偶尔在子宫内表现为与胎儿水肿相关的严重贫血,但更常见于新生儿,表现为肝肿大、早期黄疸和宫内生长受限。一些患者在儿童期或成年期发病。新生儿期过后,大多数受影响个体有终生中度贫血,通常伴有黄疸和脾肿大。即使未接受输血,随着年龄增长,由于铁吸收增加,也会发生继发性血色素沉着症。4% - 14%的受影响个体出现远端肢体异常。
诊断/检测:基于血液学检查结果怀疑CDA I诊断,并通过鉴定 或 中的双等位基因致病变异来确诊。
每周注射两次或三次肌肉注射或皮下注射干扰素IFN-α2a或IFN-α2b,或每周注射一次聚乙二醇干扰素-α2b,以提高血红蛋白水平并减少铁过载。仅对依赖输血且对干扰素治疗耐药的患者考虑进行异基因骨髓移植。必要时使用铁螯合剂治疗铁过载;对胆结石患者进行腹腔镜胆囊切除术;由骨科医生治疗脊柱侧弯;补充钙和维生素D治疗骨质疏松症;治疗髓外造血,包括定期输血、手术减容或低剂量放疗;由眼科医生治疗视力问题。每三至六个月测量一次血红蛋白,在感染时测量更频繁,从10岁开始每六至十二个月测量胆红素、铁、转铁蛋白和血清铁蛋白浓度,以监测贫血和铁过载;从10岁开始每年进行心肌和肝脏T加权MRI检查(如有条件)。从5岁开始每年进行腹部超声检查;根据需要由骨科医生检查脊柱侧弯;按照骨专科医生的建议进行骨质疏松症骨密度测量;从40岁开始每年由眼科医生评估视力并进行眼底检查,如有症状则更早进行。避免任何含铁制剂。
CDA I以常染色体隐性方式遗传。如果已知父母双方均为导致CDA I的致病变异的杂合子,则受影响个体的每个同胞在受孕时有25%的机会受到影响,50%的机会成为无症状携带者,25%的机会未受影响且不是携带者。一旦在受影响的家庭成员中鉴定出致病变异,就可以对有风险的亲属进行携带者检测以及进行产前和植入前基因检测。